BioCryst Pharmaceuticals, Inc.
HealthcareNASDAQ:BCRX · NASDAQ Global Select
+$0.20 today
Vol 2.39M · Avg 5.21M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$885.7M of revenue converted into -$458.0M of net income for the selected period. Gross margin is -13.8% and net margin is -97.5%, showing how much revenue survives after costs and taxes. EPS is $-1.78, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $874.8M +94.1% | $450.7M +36.0% | $331.4M +22.4% | $270.8M +72.3% | $157.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $19.1M +52.8% | $12.5M +167.9% | $4.7M -29.3% | $6.6M -9.2% | $7.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $855.8M +95.3% | $438.2M +34.1% | $326.8M +23.7% | $264.2M +76.3% | $149.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 97.8% +0.6pp | 97.2% -1.4pp | 98.6% +1.0pp | 97.6% +2.2pp | 95.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $166.1M -4.9% | $174.6M -19.4% | $216.6M -14.5% | $253.3M +21.3% | $208.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $348.6M +31.0% | $266.1M +24.4% | $213.9M +34.2% | $159.4M +34.1% | $118.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $514.8M +16.8% | $440.8M +2.4% | $430.5M +4.3% | $412.7M +26.0% | $327.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.4M +11.5% | $1.2M -24.7% | $1.7M +15.2% | $1.4M +84.9% | $777.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $347.7M +2614.3% | $12.8M +111.0% | -$116.3M +19.1% | -$143.9M -18.2% | -$121.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 39.7% +36.9pp | 2.8% +37.9pp | -35.1% +18.0pp | -53.1% +24.3pp | -77.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $341.0M +13508.9% | -$2.5M +97.5% | -$103.7M +30.1% | -$148.4M +16.5% | -$177.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 39.0% +39.5pp | -0.6% +30.7pp | -31.3% +23.5pp | -54.8% +58.3pp | -113.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $10.7M -27.7% | $14.7M -6.5% | $15.8M +207.7% | $5.1M +8169.4% | $62.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $78.9M -19.9% | $98.5M -9.0% | $108.2M +9.2% | $99.1M +67.1% | $59.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$73.6M +12.8% | -$84.4M +31.1% | -$122.5M -27.7% | -$95.9M -2246.5% | -$4.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $267.4M +407.5% | -$87.0M +61.6% | -$226.2M +7.4% | -$244.4M -34.4% | -$181.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 30.6% +49.9pp | -19.3% +49.0pp | -68.3% +22.0pp | -90.2% +25.4pp | -115.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $3.5M +83.2% | $1.9M +521.6% | $310.0K -88.7% | $2.7M +21.3% | $2.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | $263.9M +396.9% | -$88.9M +60.8% | -$226.5M +8.3% | -$247.1M -34.3% | -$184.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | 30.2% +49.9pp | -19.7% +48.6pp | -68.4% +22.9pp | -91.2% +25.9pp | -117.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +393.0% | -$0 +63.6% | -$1 +11.3% | -$1 -29.1% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +381.4% | -$0 +63.6% | -$1 +11.3% | -$1 -29.1% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $209.9M +1.5% | $206.7M +7.5% | $192.2M +3.4% | $185.9M +3.8% | $179.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $218.6M +5.7% | $206.7M +7.5% | $192.2M +3.4% | $185.9M +3.8% | $179.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.02B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.86B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
Ardelyx, Inc.
NASDAQ:ARDX
$1.41B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
Upstream Bio, Inc.
UPB
$331.96M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BCRX generate?
BioCryst Pharmaceuticals, Inc. (BCRX) reported $874.84M of revenue in fiscal 2025.
Is BCRX profitable?
BioCryst Pharmaceuticals, Inc. (BCRX) reported $263.86M of net income, with a net margin of 30.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.